Citations

Clear

141 citation(s) found for "Slack, S".

Diabetes Mellitus Update
Seelandt, Katherine K.

Mayo Clinic

The Journal of Continuing Education in Nursing | December 17, 2018 | Volume: 38 | Issue: 2 | Pages: 54-55

10.3928/00220124-20070301-07 | PMID 17402375 Get It

Depression in the Elderly
O’Neil, Marybeth L., O'Neil, Marybeth

Mayo Clinic

The Journal of Continuing Education in Nursing | December 17, 2018 | Volume: 38 | Issue: 1 | Pages: 14-15

10.3928/00220124-20070101-04 | PMID 17269434 Get It

Obstructive Sleep Apnea
Farnsworth, Monica M.

Mayo Clinic

The Journal of Continuing Education in Nursing | December 17, 2018 | Volume: 37 | Issue: 6 | Pages: 246-247

10.3928/00220124-20061101-08 | PMID 17144112 Get It

Unmasking Methamphetamine
Ray-Mihm, Rita J., Ray-Mihm, Rita

Mayo Clinic

The Journal of Continuing Education in Nursing | December 17, 2018 | Volume: 37 | Issue: 3 | Pages: 102-103

10.3928/00220124-20060301-08 | PMID 18814389 Get It

Models of Peer Support to Remediate Post-Intensive Care Syndrome: A Report Developed by the Society of Critical Care Medicine Thrive International Peer Support Collaborative*
McPeake, Joanne , Hirshberg, Eliotte L. , Christie, LeeAnn M., Drumright, Kelly, Hough, Catherine L. , Meyer, Joel , Wade, Dorothy , Andrews, Adair, Bakhru, Rita N. , Bates, Samantha , Barwise, John, Beesley, Sarah J. , Boehm, Leanne M. , Brown, Sheryl, Clay, Alison S. , Firshman, Penelope , Greenberg, Steven B. , Harris, Wendy, Hope, Aluko A. , Hopkins, Ramona O., Howell, David C., Jackson, James C. , Johnson, Annie, Kross, Erin K. , Lamas, Daniela, MacLeod-Smith, Belinda, Mandel, Ruth, Marshall, John C., Nackino, Megan, Quasim, Tara , Sevin, Carla M. , Slack, Andrew, Spurr, Rachel, Still, Mary, Thompson, Carol, Weinhouse, Gerald L., Wilcox, M. Elizabeth , Iwashyna, Theodore J. , Haines, Kimberley , Bastarache, Julie A. , Hill, Christopher, Hodgson, Carol Lynette , Holdsworth, Clare, Howell, David C. J., Janssen, Anna, Mikkelsen, Mark E.

Mayo Clinic

Critical Care Medicine | November 13, 2018 | Volume: 47 | Issue: 1 | Pages: e21-e27

10.1097/ccm.0000000000003497 | PMID 30422863 Get It

Objectives: Patients and caregivers can experience a range of physical, psychologic, and cognitive problems following critical care discharge. The use of peer support has been proposed as an innovative support mechanism. Design: We sought to identify technical, safety, and procedural aspects of existing operational models of peer support, among the Society of Critical Care Medicine Thrive Peer Support Collaborative. We also sought to categorize key distinctions between these models and elucidate barriers and facilitators to implementation. Subjects and Setting: Seventeen Thrive sites from the United States, United Kingdom, and Australia were represented by a range of healthcare professionals. Measurements and Main Results: Via an iterative process of in-person and email/conference calls, members of the Collaborative defined the key areas on which peer support models could be defined and compared, collected detailed self-reports from all sites, reviewed the information, and identified clusters of models. Barriers and challenges to implementation of peer support models were also documented. Within the Thrive Collaborative, six general models of peer support were identified: community based, psychologist-led outpatient, models-based within ICU follow-up clinics, online, groups based within ICU, and peer mentor models. The most common barriers to implementation were recruitment to groups, personnel input and training, sustainability and funding, risk management, and measuring success. Conclusions: A number of different models of peer support are currently being developed to help patients and families recover and grow in the postcritical care setting.
Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
Agasthi, Pradyumna , Narayanasamy, Hemalatha , Sorajja, Dan , Slack, James L., Mookadam, Farouk , Slack, James

Mayo Clinic

Case Reports in Cardiology | September 30, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-4

10.1155/2018/3953579 | PMID 30363961 Get It

Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia. We present a case of cardiomyopathy associated with decitabine used for secondary acute myelogenous leukemia. The patient presented with new heart failure symptoms and an ejection fraction decline.
Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.
Wright, George W. , Slack, Graham W. , Pinyol, Magda, Boyle, Merrill, Villa, Diego , Rosenwald, Andreas , Staudt, Louis M. , Gascoyne, Randy D. , (LLMPP), on behalf of the Leukemia Lymphoma Molecular Profiling Project, Scott, David W. , Abrisqueta, Pau , Jares, Pedro , Mottok, Anja , Royo, Cristina , Clot, Guillem , Steidl, Christian , Connors, Joseph M. , Rimsza, Lisa M. , Campo, Elı́as , (LLMPP), on behalf of the Leukemia Lymphoma Molecular Profiling Project, Wright, George

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7510-7510

10.1200/jco.2016.34.15_suppl.7510 Get It

Single dose versus multiple doses of rituximab for preemptive therapy of Epstein–Barr virus reactivation after hematopoietic cell transplantation
Jain, Tania , Grys, Thomas E. , Kung, Shu Ting, Shah, Vishal , Betcher, Jeffrey, Slack, James L., Leis, José F., Khera, Nandita , Noël, Pierre, Palmer, Jeanne , Sproat, Lisa Z., Shah, Vishal S, Betcher, Jeffrey A, Palmer, Jeanne M., Jain, Tania , Kosiorek, Heidi , Shah, Vishal , Grys, Thomas E

Mayo Clinic

Leukemia & Lymphoma | July 6, 2018 | Volume: 60 | Issue: 1 | Pages: 110-117

10.1080/10428194.2018.1459603 | PMID 29979906 Get It

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology
King, Rebecca L. , Jiang, Aixiang , Horn, Heike , Mottok, Anja , Farinha, Pedro , Slack, Graham W. , Ennishi, Daisuke , Schmitz, Norbert , Pfreundschuh, Michael , Nowakowski, Grzegorz S. , Gascoyne, Randy D. , Ott, German , Macon, William R. , Rosenwald, Andreas , Scott, David W. , Staiger, Annette M. , Ben‐Neriah, Susana , Kahl, Brad S. , Connors, Joseph M. , Farinha, Pedro

Mayo Clinic

Blood | February 23, 2018 | Volume: 131 | Issue: 18 | Pages: 2060-2064

10.1182/blood-2017-12-820605 | PMID 29475959 Get It

Key Points HGBL-DH/TH makes up 8% of de novo DLBCL, with HGBL-DH/TH with BCL2 rearrangement being a GCB phenomenon. Restricting FISH testing to tumors with dual protein expression and GCB subtype results in testing <15% of tumors, but missing ∼35% of HGBL-DH/TH.
Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis
Tefferi, Ayalew , Partain, Daniel K. , Palmer, Jeanne , Slack, James L., Litzow, Mark, Patnaik, Mrinal M. , Palmer, Jeanne M., Litzow, Mark L, Patnaik, Mrinal , Partain, Daniel K , Roy, Vivek , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | February 1, 2018 | Volume: 93 | Issue: 5 | Pages: 649-654

10.1002/ajh.25053 | PMID 29388258 Get It

AbstractThe prognostic importance of genetic information in primary myelofibrosis (PMF) was recently highlighted in a study of over 1000 cytogenetically‐annotated patients; 5‐year survival rates were 8% for very high risk (VHR), 27% “unfavorable” and 45% “favorable” karyotype. The current study addresses the practice‐relevant question of whether or not allogeneic hematopoietic stem cell transplant (HCT) can overcome the detrimental survival effect of VHR or unfavorable karyotype. The study included 67 patients with PMF or secondary MF who received HCT at the Mayo Clinic and in whom pretransplant cytogenetic information was available. Dynamic international prognostic scoring system (DIPSS) risk distribution was 13% high, 66% intermediate‐2 and 21% intermediate‐1. Cytogenetic risk distribution was 11% VHR, 34% unfavorable and 55% favorable. At median post‐HCT follow‐up of 60 months for living patients (range 34‐170), 28 (42%) deaths were recorded. Five‐year survival was 62% and was not affected by VHR or unfavorable karyotype (P = .68). The salutary effect of HCT in patients with VHR or unfavorable karyotype was also apparent during analysis of a combined dataset that included a nontransplant cohort of 383 patients with PMF; multivariable analysis of the combined dataset (n = 450) resulted in HRs (95% CI) of 2.4 (1.6‐3.6) for absence of transplant, 3.3 (2.2‐4.8) for VHR karyotype, 1.6 (1.2‐2.1) for unfavorable karyotype, 2.9 (2.0‐4.2) for DIPSS high and 1.7 (1.4‐2.2) for DIPSS intermediate‐2. These observations were further confirmed by analysis of more stringently matched case‐control subset cohorts and provide the evidence for the therapeutic preference of HCT in cytogenetically high risk patients with MF.